ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations
PD-1-Naïve Patients More Likely To Derive Benefit
Several studies of LAG-3-targeting drugs combined with PD-1 and PD-L1 inhibitors are being presented at ASCO • Source: Shutterstock 
